1de Koning EJ, Bonner-Weir S, Rabelink TJ. Preservation of 13- cell function by targeting Q-cell mass [J]. Trends Pharmacol Sci,2008,29(4) :218-227.
2UK prospective Diabetes study Group. U. K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes:a progressive disease[J]. Diabetes, 1995, 44(11): 1249 1258.
3Nauck M. Glucagon-like pretide-1 in type 2 diabetes: the cell and beyond[J]. Diabetes Obes Metab, 2008,10(s3) : 2-13.
4Wright AD,Cull CA,Macleod KM,et al. Hypoglycemia in type 2 diabetic patients randomized to and maintained on monotherapy with diet, sulfonylurea, metformin, or insulin for 6 years from diagnosis: UKPDS73 [ J ]. J Diabetes Complications, 2006,20 (6) :395-401.
5UK prospective Diabetes study (UKPDS) Group. Effect of intensive ' blood-glucose control with metformin complications in overweight patients with type 2 diabetes (UKPDS 34)[J]. Lancet,1998,352(9131) :854-865.
6Kreymann B, Williams G, Ghatei MA, et al. Glucagon-like pretide-1 7-36: a physiological incretin in man[J]. Lancet, 1987,2(8571), 1300-1304.
7Vilsboll T,Krarup T,Madsbad S,et al. Defeetive amplification of the late phase insulin response to glucose by GIP in obese type g diabetic patients[J]. Diabetologia,2002,45(8):1111- 1119.
8Drucker DJ, Nauck MA. The incretin system: glucagon-llke pretide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes[J]. Lancet,2006,368(9548).. 1696-1705.
9Hoist JJ. The physiology of glucagon-like peptide [J]. Physio Rev, 2007,87(4) : 1409-1439.
10Gromada J,Bokvist K,Ding WG, et al. Glucagon-like pretide 1 (7-36) amide stimulates exocytosis in human pancreatic beta- cells by both proximal and distal regulatory steps in stimulus- secretion coupling[J]. Diabetes, 1998,47 ( 1 ) : 57-65.
